Navigation Links
ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
Date:1/21/2017

REDWOOD CITY, Calif., Jan. 20, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, presented new Phase 1b clinical data on the Company's lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at the 2017 Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology (ASCO), taking place January 19-21, 2017 in San Francisco, CA.

"AM0010 induces the expansion of novel T cell clones and activated CD8+ T cells in the blood and tumors of our patients," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  "Our Phase 1b study in advanced pancreatic cancer patients evaluates the additive or synergistic anti-tumor function of AM0010 in combination with the FOLFOX chemotherapy regimen. We are excited to present for the first time the data from this study in which we achieved a 16% objective response rate, including 2 complete responses.  To advance our AM0010 program, we began enrolling patients in an international Phase 3 randomized pivotal clinical trial of AM0010 in combination with FOLFOX as second-line therapy for advanced metastatic pancreatic cancer."

In the Phase 1b clinical trial, 21 patients with advanced pancreatic cancer were treated with AM0010 in combination with FOLFOX.  The patients had previously progressed on a prior gemcitabine containing regimen and had a median number of two prior therapies (ranging from 1 to 5).  Fifteen of 19 (79%) patients who were evaluable for tumor responses had disease control according to the immune-related Response Criteria (irRC).  Three (16%) had objective responses, including 2 that achieved a complete response and 1 partial response.  The median progression free survival of all 21 treated patients was 3.5 months and the median overall survival has not been reached after a median follow-up of 10.5 months (3.8-15.6+ months). AM0010 in combination with FOLFOX has been well tolerated.

About AM0010 Poster Presentation at ASCO Gastrointestinal Cancers Symposium
Abstract Title: Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). (Abstract #399)
Lead Author: J. Randolph Hecht, M.D., Professor of Clinical Medicine and Director of the Gastrointestinal Oncology Program, David Geffen School of Medicine, UCLA
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date: Friday, January 20, 2017, 12:30-2:00 PM and 5:30-6:30 PM (Pacific Time)
Location: Level 1, West Hall (Board #J5)

About AM0010
AM0010 is a long-acting form of recombinant human IL-10, which has shown sustained anti-tumor effects and a good safety/tolerability profile in patients from multiple oncology indications. Due to its enhanced half-life, AM0010 has strong immune-stimulating effects that induce the activation, proliferation, and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in patients. CD8+ T cells mediate the tumor clearing effect of this immuno-oncology agent.

The U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted AM0010 Orphan Drug designation for the treatment of pancreatic cancer. The FDA also granted Fast Track designation for AM0010 in combination with FOLFOX as a second-line therapy in patients with pancreatic cancer.

ARMO is conducting an international Phase 3 randomized pivotal clinical trial with AM0010 for the treatment of pancreatic ductal adenocarcinoma (PDAC). In a Phase 1/1b clinical trial in 350 cancer patients across more than 14 different types of cancer, AM0010 demonstrated the ability to increase the number of activated CD8+ T cells in the blood and tumors of patients and achieve objective tumor responses, including partial and complete responses, in patients treated with AM0010 as a single agent or in combination with chemotherapeutic drugs or anti-PD-1 checkpoint inhibitors.

About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010, stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells.  CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.

In addition, ARMO is developing a robust immuno-oncology pipeline that includes validated product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies. For more information, please visit www.armobio.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/armo-biosciences-presents-new-phase-1b-clinical-data-for-am0010-in-advanced-pancreatic-cancer-patients-at-2017-gastrointestinal-cancers-symposium-300394226.html


'/>"/>
SOURCE ARMO BioSciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences Provides Portfolio Update
2. Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies
3. Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
4. Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
5. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of Pancreatic Cancer
6. Drug Makers Stocks Under Scanner -- Novo Nordisk, Synergy Pharma, Pernix Therapeutics, and Apricus Biosciences
7. Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting
8. Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
9. Arkis BioSciences Closes $3.4 Million Series-A Investment
10. Leading BioSciences Appoints Greg Doyle as Chief Executive Officer
11. Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):